Bridging Educational Gaps in Non-Clear Cell RCC: Essential Insights & Resources
- CancerNetwork hosted a panel discussion focusing on renal cell carcinoma (RCC), particularly clear and non-clear cell types.
- Moshe Ornstein, a medical oncologist at the Cleveland Clinic.
- Tawagi stated that about 80% of kidney cancers are clear cell RCC.
Panel Discussion on Renal Cell Carcinoma (RCC)
CancerNetwork hosted a panel discussion focusing on renal cell carcinoma (RCC), particularly clear and non-clear cell types. The discussion highlighted treatment differences and challenges in educating patients about non-clear cell RCC.
Panel Leaders and Participants
The panel was led by Dr. Moshe Ornstein, a medical oncologist at the Cleveland Clinic. Other panelists included Dr. Karine Tawagi from the University of Illinois, Dr. Mahdi Taha from Florida Cancer Specialists, and Dr. Nataliya Mar from the University of California Irvine.
Understanding RCC Types
Dr. Tawagi stated that about 80% of kidney cancers are clear cell RCC. Non-clear cell RCC is a diverse group. The most common type is papillary RCC, making up 15% to 20% of cases. In 2022, the World Health Organization reclassified papillary RCC, eliminating previous subtypes. Chromophobe RCC accounts for up to 10% of cases and has a moderate prognosis. Collecting duct carcinoma and medullary RCC are rare and more aggressive types.
Patient Demographics and Risk Factors
Non-clear cell RCC tends to affect older adults and has a slight male predominance. Risk factors for clear cell RCC include smoking, obesity, and hypertension. Genetic syndromes like von Hippel-Lindau and tuberous sclerosis are also associated with certain kidney cancer types.
Challenges in Non-Clear Cell RCC Care
Dr. Taha emphasized the scarcity of resources for non-clear cell RCC. Community oncologists often lack the extensive resources found in major cancer centers. Educating patients about their unique prognosis is critical during consultations.
Dr. Mar added that interpreting clinical trial data for non-clear cell RCC is difficult due to small sample sizes in studies. The challenge lies in applying broad results to individual patients with varying histologies. Limited treatment options further complicate care decisions.
Final Insights
Dr. Ornstein concluded by underscoring the need for improved education for both providers and patients. With the rising complexities of RCC subtypes, better resources are necessary for effective treatment and care.